GPX4 Inhibitor Discovery

About XtalPi

Founded in 2014 by MIT physicists, XtalPi has evolved from a pioneer in crystal structure prediction (CSP) into a comprehensive AI and automation platform for drug discovery. The company leverages a proprietary 'Hybrid AI + QM Discovery Engine' that combines quantum mechanics, machine learning, and robotic labs to design, predict, and synthesize novel drug candidates with high efficiency. With over 80 partners in pharma and biotech, a team of 1000+ employees, and a proven track record including contributions to Paxlovid's development, XtalPi is positioned as a key technology enabler in the rapidly growing AI-driven drug discovery sector.